+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID07685769

Evaluating Safety and Tolerability of Rimegepant 75 mg ODT for Acute Migraine Treatment in Adults in India with Previous Triptan Issues

Led by Pfizer · Updated on 2026-10-15

60

Participants Needed

7

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and tolerability of rimegepant 75 mg orally disintegrating tablet ODT for the acute treatment of migraine, with or without aura, in adult patients in India who have previously had an insufficient response, intolerance, or contraindications to triptans. This is a multicenter, single-arm, open-label Phase 4 study enrolling approximately 60 participants to better understand the safety profile of rimegepant in this population. Participants who qualify will be enrolled within 28 days after screening. Each participant will receive a single blister card containing one 75 mg ODT tablet of rimegepant to be taken as needed during a migraine attack within 30 days of the baseline visit. After taking the medication, participants must notify the study site by phone within 12 hours, and then will receive a follow-up phone call about 2 days later to assess any adverse events or side effects. Participant satisfaction with the medication will also be evaluated during this call. Finally, participants will attend an end-of-study visit 28 to 35 days after dosing. Participation lasts up to 93 days, including up to 28 days for screening, a 30-day treatment window, and up to 35 days of follow-up after dosing. During the study, safety is monitored through phone calls and the end-of-study visit. Researchers will measure treatment-emergent adverse events, serious adverse events, vital sign abnormalities, and participant satisfaction using a specific questionnaire. This careful monitoring aims to gather detailed information on the use of rimegepant for migraine treatment in adults in India.

CONDITIONS

Brief Title

A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India

Research Team

P

Pfizer CT.gov Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here